Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Corvus Pharmaceuticals (CRVS) to $11 from $12 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1 report. With quarterly financials less relevant, the focus is on the company’s recent Phase 1 data for lead asset soquelitinib in atopic dermatitis, where Mizuho is “very constructive” on soquelitinib’s profile, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Biotech Alert: Searches spiking for these stocks today
- Largest borrow rate increases among liquid names
- Corvus Pharmaceuticals Reports Strong Q1 2025 Earnings
- Corvus Pharmaceuticals price target raised to $17 from $15 at Oppenheimer
- Corvus Pharmaceuticals: Promising AD Treatment Developments and Strategic Expansion Justify Buy Rating